BSE: ASTRAZEN - AstraZeneca Pharma India Limited

Rentabilité sur six mois: +18.21%
Rendement en dividendes: +0.25%

Calendrier des promotions AstraZeneca Pharma India Limited

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names.

plus de détails
The company also offers medicines for diabetes and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

ISIN INE203A01020
Industry Pharmaceuticals
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 0.2508
Дивиденд ао 24
Сайт https://www.astrazeneca.in
Цена ао 8373.75
Changement de prix par jour: +1.43% (8373.75)
Changement de prix par semaine: +1.22% (8391.5)
Changement de prix par mois: +22.91% (6910.9)
Changement de prix sur 3 mois: +33.16% (6378.7)
Changement de prix sur six mois: +18.21% (7185.65)
Changement de prix par an: +59.67% (5319.75)
Evolution du prix sur 3 ans: +223.78% (2623.35)
Evolution du prix sur 5 ans: +205.11% (2783.9)
Evolution des prix depuis le début de l'année: +15.92% (7327.65)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 10.32 1
P/BV 18.77 1
P/E 82.75 1
EV/EBITDA 59.98 1
Total: 3.25

Efficacité

Nom Signification Grade
ROA, % 14.98 4
ROE, % 22.69 7
Total: 3.17

Dividendes

Nom Signification Grade
Div yield, % 0.2508 0.63
DSI 1 10
Total: 3.66

Devoir

Nom Signification Grade
Debt/EBITDA 0.0477 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 55.75 7
Rentabilité Ebitda, % 12.95 2
Rentabilité EPS, % 122.91 10
Total: 5.8
Plus de détails

ETFPartager, %Rentabilité pour l'année, %Dividendes, %
iShares MSCI India Small-Cap ETF 0.10099 0.4625 0.96163
SPDR Portfolio Emerging Markets ETF 0.05558 11.59 3.1879
SPDR S&P Emerging Markets Small Cap ETF 0.0496 5.46 3.03583
iShares MSCI Emerging Markets Small-Cap ETF 0.0407 7.67 2.7853
Vanguard FTSE All-World ex-US Small-Cap ETF 0.02 9.39 3.09932
SPDR Portfolio MSCI Global Stock Market ETF 0.00336 17.99 2.19607
Dimensional Emerging Markets Core Equity 2 ETF 0.00252 15.96 3.34087
Avantis Emerging Markets Equity ETF 0.0004 8.77 3.60513
Vanguard ESG International Stock ETF 0 6.39 3.07501
0.039.32.81

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Pratap Rudra Bhuvanagiri Legal Counsel 3.73M
Ms. Manasa R. Company Secretary & Compliance Officer N/A
Ms. Smita Saha Vice President of Human Resources N/A 1970 (55 années)
Dr. Sanjeev Kumar Panchal MD, Country President & Director 21.15M 1977 (48 années)
Ms. Bhavana Agrawal Whole-Time Director & CFO N/A
Mr. Ayush Kumar Agarwal Interim Business Unit Head of Oncology & Director of Commercial Excellence N/A
Mr. Praveen Akkinepally Head of Oncology Business Unit N/A
Mr. Vinay Sharma Business Unit Head - Rare Disease unit
Mr. Pankaj S Jain Legal Head

Adresse: India, Bengaluru, Manyata Embassy Business Park - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.astrazeneca.in